Citigroup’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.92M | Buy |
244,261
+233,490
| +2,168% | +$3.76M | ﹤0.01% | 1984 |
|
|
2025
Q4 | $174K | Sell |
10,771
-269,885
| -96% | -$3.57M | ﹤0.01% | 4065 |
|
|
2025
Q3 | $3.42M | Sell |
280,656
-18,538
| -6% | -$256K | ﹤0.01% | 2259 |
|
|
2025
Q2 | $3.38M | Buy |
299,194
+150,967
| +102% | +$1.85M | ﹤0.01% | 2227 |
|
|
2025
Q1 | $1.71M | Sell |
148,227
-179,069
| -55% | -$1.83M | ﹤0.01% | 2846 |
|
|
2024
Q4 | $2.77M | Buy |
327,296
+21,792
| +7% | +$226K | ﹤0.01% | 2531 |
|
|
2024
Q3 | $3.54M | Buy |
305,504
+19,440
| +7% | +$245K | ﹤0.01% | 2141 |
|
|
2024
Q2 | $3.37M | Buy |
286,064
+3,181
| +1% | +$37.1K | ﹤0.01% | 1928 |
|
|
2024
Q1 | $3.35M | Buy |
282,883
+974
| +0.3% | +$13K | ﹤0.01% | 2016 |
|
|
2023
Q4 | $3.45M | Buy |
281,909
+4,991
| +2% | +$45.4K | ﹤0.01% | 1841 |
|
|
2023
Q3 | $2.67M | Sell |
276,918
-22,890
| -8% | -$234K | ﹤0.01% | 1804 |
|
|
2023
Q2 | $2.7M | Buy |
299,808
+22,902
| +8% | +$211K | ﹤0.01% | 1942 |
|
|
2023
Q1 | $2.18M | Sell |
276,906
-165
| -0.1% | -$1.23K | ﹤0.01% | 1962 |
|
|
2022
Q4 | $1.87M | Buy |
277,071
+276,402
| +41,316% | +$1.48M | ﹤0.01% | 2092 |
|
|
2022
Q3 | $10K | Sell |
669
-1,478
| -69% | -$20.7K | ﹤0.01% | 4992 |
|
|
2022
Q2 | $21K | Sell |
2,147
-6,290
| -75% | -$69.4K | ﹤0.01% | 4973 |
|
|
2022
Q1 | $124K | Sell |
8,437
-45,690
| -84% | -$656K | ﹤0.01% | 4319 |
|
|
2021
Q4 | $716K | Buy |
54,127
+25,139
| +87% | +$400K | ﹤0.01% | 3557 |
|
|
2021
Q3 | $506K | Sell |
28,988
-68,829
| -70% | -$1.39M | ﹤0.01% | 3597 |
|
|
2021
Q2 | $2.34M | Buy |
97,817
+73,132
| +296% | +$1.91M | ﹤0.01% | 2546 |
|
|
2021
Q1 | $634K | Buy |
24,685
+21,109
| +590% | +$555K | ﹤0.01% | 3297 |
|
|
2020
Q4 | $68K | Buy |
3,576
+2,658
| +290% | +$45.6K | ﹤0.01% | 5825 |
|
|
2020
Q3 | $12K | Sell |
918
-1,362
| -60% | -$17K | ﹤0.01% | 6502 |
|
|
2020
Q2 | $28K | Sell |
2,280
-1,607
| -41% | -$17.1K | ﹤0.01% | 6365 |
|
|
2020
Q1 | $30K | Buy |
3,887
+1,357
| +54% | +$18.3K | ﹤0.01% | 6409 |
|
|
2019
Q4 | $45K | Buy |
2,530
+1,951
| +337% | +$25.5K | ﹤0.01% | 6389 |
|
|
2019
Q3 | $6K | Sell |
579
-2,681
| -82% | -$43.3K | ﹤0.01% | 7274 |
|
|
2019
Q2 | $72K | Sell |
3,260
-8,978
| -73% | -$211K | ﹤0.01% | 6155 |
|
|
2019
Q1 | $350K | Buy |
+12,238
| New | +$265K | ﹤0.01% | 4546 |
|
|
2016
Q2 | – | Sell |
-725
| Closed | -$7K | – | 7230 |
|
|
2016
Q1 | $7K | Buy |
725
+461
| +175% | +$8.26K | ﹤0.01% | 6906 |
|
|
2015
Q4 | $13K | Buy |
264
+260
| +6,500% | +$13.6K | ﹤0.01% | 6688 |
|
|
2015
Q3 | $0 | Sell |
4
-7
| -64% | -$597 | ﹤0.01% | 7534 |
|
|
2015
Q2 | $1K | Buy |
+11
| New | +$1.09K | ﹤0.01% | 7304 |
|
Other funds holding KALV
VA
FLSM
SCM
TCM
SCM
Citigroup's KALV Position: Q1 2026 in Review
Citigroup increased its KalVista Pharmaceuticals (KALV) stake by 2,168% in Q1 2026, buying an estimated $3.76M and bringing the position to 244,261 shares worth $4.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1984.
Citigroup first reported a position in KALV in Q2 2015 and has held it in 33 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.
- Citigroup held 244,261 shares of KalVista Pharmaceuticals worth $4.92M as of Q1 2026.
- Citigroup bought 233,490 KalVista Pharmaceuticals shares in Q1 2026, an estimated $3.76M.
- KalVista Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1984 holding.
- Citigroup first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 33 quarters since.
- 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.